Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)

China flag China · Delayed Price · Currency is CNY
30.99
-0.16 (-0.51%)
Jan 22, 2026, 3:00 PM CST
52.74%
Market Cap12.59B
Revenue (ttm)1.62B
Net Income (ttm)424.54M
Shares Out406.18M
EPS (ttm)1.06
PE Ratio29.15
Forward PE27.67
Dividend0.29 (0.93%)
Ex-Dividend DateJun 20, 2025
Volume3,471,718
Average Volume7,323,465
Open31.02
Previous Close31.15
Day's Range30.59 - 31.73
52-Week Range18.70 - 35.58
Beta-0.10
RSI66.59
Earnings DateApr 17, 2026

About Aurisco Pharmaceutical

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides dexamethasone is used to treat skin diseases; fluticasone propionate preparations are used to treat asthma and allergic rhinitis; fluticasone furoate preparations are used to treat asthma, allergic rhinitis, a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 1,784
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 605116
Full Company Profile

Financial Performance

In 2024, Aurisco Pharmaceutical's revenue was 1.48 billion, an increase of 16.89% compared to the previous year's 1.26 billion. Earnings were 354.79 million, an increase of 22.59%.

Financial Statements